CTX Stock Overview
A dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Crescita Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.55 |
| 52 Week High | CA$0.69 |
| 52 Week Low | CA$0.36 |
| Beta | 1.69 |
| 1 Month Change | -14.06% |
| 3 Month Change | -11.29% |
| 1 Year Change | 29.41% |
| 3 Year Change | -16.67% |
| 5 Year Change | -42.11% |
| Change since IPO | -59.85% |
Recent News & Updates
Risks To Shareholder Returns Are Elevated At These Prices For Crescita Therapeutics Inc. (TSE:CTX)
Oct 25
We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope
May 30Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Crescita Therapeutics Inc. (TSE:CTX)
Oct 25We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope
May 30Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge
Jan 04Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?
Nov 18Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)
May 05Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 10
Shareholder Returns
| CTX | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -1.8% | -0.5% | -2.6% |
| 1Y | 29.4% | -26.7% | 15.2% |
Return vs Industry: CTX exceeded the Canadian Pharmaceuticals industry which returned -26.7% over the past year.
Return vs Market: CTX exceeded the Canadian Market which returned 15.2% over the past year.
Price Volatility
| CTX volatility | |
|---|---|
| CTX Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 12.0% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: CTX has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: CTX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Serge Verreault | www.crescitatherapeutics.com |
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers and DuraPeel that supports the development of patented formulations that can deliver actives into or through the skin.
Crescita Therapeutics Inc. Fundamentals Summary
| CTX fundamental statistics | |
|---|---|
| Market cap | CA$10.55m |
| Earnings (TTM) | -CA$2.74m |
| Revenue (TTM) | CA$17.40m |
0.6x
P/S Ratio-3.9x
P/E RatioIs CTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTX income statement (TTM) | |
|---|---|
| Revenue | CA$17.40m |
| Cost of Revenue | CA$7.73m |
| Gross Profit | CA$9.67m |
| Other Expenses | CA$12.41m |
| Earnings | -CA$2.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 55.58% |
| Net Profit Margin | -15.73% |
| Debt/Equity Ratio | 0% |
How did CTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:39 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Crescita Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|